(ALIF-B) AddLife AB (publ) - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0014401378

ALIF-B: Laboratory Equipment, Medical Devices, Diagnostics Reagents, Consumables

AddLife AB (publ) is a multifaceted company that, along with its subsidiaries, supplies a wide range of equipment, consumables, and reagents to various sectors, including healthcare, research institutions, colleges, universities, the food industry, and pharmaceutical companies. This diverse customer base benefits from the company's broad portfolio of products and services, which are designed to meet the specific needs of each industry. The company's operations are divided into two main segments: Labtech and Medtech, each catering to distinct markets and requirements.

The Labtech segment is focused on providing solutions and services for diagnostics, biomedical research, and laboratory equipment. This includes a variety of products such as plastic consumables, cell biology tools, reagents, and other laboratory instruments. These offerings are crucial for research and development activities in the life sciences sector, enabling scientists and researchers to conduct experiments, analyze data, and develop new treatments and therapies. By supplying these essential tools and services, AddLife AB (publ) plays a significant role in advancing scientific knowledge and innovation in the field.

In contrast, the Medtech segment is centered on providing medical device products for a range of applications, including surgery, thoracic medicine, neurology, wound care, anesthesia, intensive care, ear, nose, and throat treatments, ostomies, and home healthcare. Additionally, this segment offers assistive technology solutions designed to improve the quality of life for senior citizens and disabled children. These products and services are vital for healthcare providers, enabling them to deliver high-quality patient care and improve outcomes. The Medtech segment's diverse product portfolio reflects the company's commitment to addressing the complex and evolving needs of the healthcare industry.

AddLife AB (publ) has a significant geographical presence, operating in numerous countries across Europe, including Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, and Germany, as well as internationally. This extensive reach allows the company to serve a broad customer base and respond to the unique requirements of different markets. Founded in 1906 and headquartered in Stockholm, Sweden, AddLife AB (publ) has a long history of providing essential products and services to the life sciences and healthcare sectors. With its strong foundation and diversified business model, the company is well-positioned to continue supporting innovation and growth in these critical industries.

Additional Sources for ALIF-B Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ALIF-B Stock Overview

Market Cap in USD 1,548m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception

ALIF-B Stock Ratings

Growth 5y 30.9%
Fundamental 29.8%
Dividend 26.9%
Rel. Strength Industry 1777
Analysts -
Fair Price Momentum 131.24 SEK
Fair Price DCF 147.57 SEK

ALIF-B Dividends

Dividend Yield 12m 0.36%
Yield on Cost 5y 0.70%
Annual Growth 5y 0.00%
Payout Consistency 76.3%

ALIF-B Growth Ratios

Growth Correlation 3m -11.8%
Growth Correlation 12m 71.9%
Growth Correlation 5y -14.7%
CAGR 5y 14.13%
CAGR/Mean DD 5y 0.33
Sharpe Ratio 12m 0.90
Alpha 10.60
Beta 0.93
Volatility 57.86%
Current Volume 36.2k
Average Volume 20d 94.1k
What is the price of ALIF-B stocks?
As of January 22, 2025, the stock is trading at SEK 139.10 with a total of 36,212 shares traded.
Over the past week, the price has changed by +3.20%, over one month by +1.46%, over three months by -13.47% and over the past year by +31.30%.
Is AddLife AB (publ) a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, AddLife AB (publ) is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 29.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALIF-B as of January 2025 is 131.24. This means that ALIF-B is currently overvalued and has a potential downside of -5.65%.
Is ALIF-B a buy, sell or hold?
AddLife AB (publ) has no consensus analysts rating.
What are the forecast for ALIF-B stock price target?
According to ValueRays Forecast Model, ALIF-B AddLife AB (publ) will be worth about 144 in January 2026. The stock is currently trading at 139.10. This means that the stock has a potential upside of +3.49%.
Issuer Forecast Upside
Wallstreet Target Price 165.5 19%
Analysts Target Price - -
ValueRay Target Price 144 3.5%